Ad26.COV2.S

Also known as Ad26COVS1, J7, Janssen vaccine, Jhon, Dutch vaccine, Jcovden

COVID-19 vaccine of Johnson & Johnson

Key facts

Target: SARS-CoV-2
Vaccine type: Viral vector
Trade names: Jcovden
Other names: Ad26.COV2.S JNJ-78436735 Ad26COVS1 VAC31518 COVID-19 Vaccine Janssen Johnson & Johnson COVID ‑ 19 vaccine
Ahfs drugs com: Multum Consumer Information
License data: United States</span>"}]]}'>US DailyMed : Janssen COVID-19 Vaccine
Pregnancy category: Australia</span>"}]]}'>AU : B1
Routes of administration: Intramuscular
Atc code: J07BN02 ( WHO )
Cas number: 2541607-46-7
Drugbank: DB15857
Unii: JT2NS6183B

Article

The Janssen COVID‑19 vaccine, (Ad26.COV2.S) sold under the brand name Jcovden, is a COVID‑19 vaccine that was developed by Janssen Vaccines in Leiden, Netherlands, and its Belgian parent company Janssen Pharmaceuticals, a subsidiary of American company Johnson & Johnson.

It is a viral vector vaccine based on a human adenovirus that has been modified to contain the gene for making the spike protein of the SARS-CoV-2 virus that causes COVID‑19. The body's immune system responds to this spike protein to produce antibodies. The vaccine requires only one dose and does not need to be stored frozen.